Beneficial effect of tibolone on mood, cognition, well-being, and sexuality in menopausal women

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 3, 2006, Pages 299-307

  Genezzani, Andrea Riccardo ^a   Pluchino, Nicola ^a   Bernardi, Francesca ^a   Centofanti, Manolo ^a   Luisi, Michele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Menopause; Mood; Tibolone; Well being and sexuality

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANDROSTERONE DERIVATIVE; BETA ENDORPHIN; BETA LIPOTROPIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIHYDROANDROSTERONE ENANTHATE; ERYTHROPOIETIN; ESTRADIOL; ESTRADIOL BENZOATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ESTROGEN; FLUOXETINE; NORGESTREL; PRASTERONE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TIBOLONE; UNCLASSIFIED DRUG;

ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; MAJOR DEPRESSION; MENOPAUSAL SYNDROME; MOOD; MOOD DISORDER; NONHUMAN; OVARY POLYCYSTIC DISEASE; QUALITY OF LIFE; SEXUAL FUNCTION; SEXUALITY; STRUCTURE ACTIVITY RELATION; SWEATING; WELLBEING;

EID: 33750078399     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.3.299     Document Type: Article

References (63)

1. Albertazzi P, Di Micco R, Zanardi E. 1998. Tibolone: a review. Maturitas, 30:295-305.
2. Albertazzi P, Natale V, Barbolini C, et al. 2000. The effect of tibolone versus continuous combined norethisterone acetate and oestradiol on memory, libido and mood of postmenopausal women: a pilot study. Maturitas, 36:223-9.
3. Aleem F, McIntosh T. 1984. Elevated levels of plasma beta-endorphin in a group of women with polycystic ovarian disease. Fertil Steril, 42:686-9.
4. Aleem FA, McIntosh T. 1985. Menopausal syndrome: plasma levels of endorphin in postmenopausal women using a specific radioimmunoassay. Maturitas, 13:76-84.
5. Baulieu EE. 1991. Neurosteroids: a new function in the brain. Biol Cell, 71:3-10.
6. Baulieu EE. 1997. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res, 52:1-32.
7. Baulieu EE, Robel P, Schumacher M. 2001. Neurosteroids: beginning of the story. Int Rev Neurobiol, 46:1-32.
8. Berlanga C, Mendieta D, Alva G, et al. 2003. Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression. J Womens Health (Larchmt), 12:33-9.
9. Castelo-Branco C, Vicente JJ, Figueras F, et al. 2000. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas, 34:161-8.
10. Crona NGL, Samsioe UB, Silfverstolpe G. 1988. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas, 9:303-8.
11. Davis S. 1999. Androgen replacement therapy: a commentary. J Clin Endocrinol Metab, 84:1886-91.
12. Davis SR. 2002a. The effects of tibolone on mood and libido. Menopause, 9:162-70
13. Davis SR. 2002b. When to suspect androgen deficiency other than at menopause. Fertil Steril, 77: S68-71.
14. Davis SR, Burger H. 1996. Androgen and postmenopausal women. J Clin Endocrinol Metab, 81:2759-63.
15. Davis S, Tran J. 2001. Testosterone influences libido and well-being in women. Trends Endocrinol Metab, 12:33-7.
16. de Gooyer ME, Deckers GH, Schoonen WGEJ, et al. 2003. Receptor profiling and endocrine interactions of tibolone. Steroids, 68:21-30.
17. de Gooyer ME, Overklift Vaupel Kleyn GT, Smits KC, et al. 2001. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol, 183:55-62.
18. Dören M, Ruebig A, Holzgreve W. 2001. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril, 75:554-8.
19. Fluck E, File SE, Rymer J. 2002. Cognitive effects of 10 years of hormone-replacement therapy with tibolone. J Clin Psychopharmacol, 22:62-7.
20. Forman L, Hartwell M, Cater J. 1985. Beta-endorphin in the male rat pituitarytestosterone influences the effects of cocaine. Brain Res Bull, 25:65-8.
21. Genazzani AR. 2004. HRT. In Climacteric and aging brain. London: The Parthenon Publishing Group.
22. Genazzani AR, Bernardi F, Pluchino N, et al. 2005. Endocrinology of menopausal transition and its brain implications. CNS Spectr, 10:449-57.
23. Genazzani AR, Bernardi F, Pluchino N, et al. 2006. Effect of tibolone administration on central and peripheral levels of allopregnanolone and β-endorphin in female rats. Menopause, 13:57-64.
24. Genazzani AR, Palumbo MA, de Micheroux AA, et al. 1995. Evidence for a role for the neurosteroid allopregnanolone in the modifications of reproductive function in female rats. Eur J Endocrinol, 133:375-80.
25. Genazzani AR, Petraglia F, Facchinetti F, et al. 1984. Increase of proopiomelanocortin-related peptides during subjective menopausal flushes. Am J Obstet Gynecol, 149:775-9.
26. Genazzani AR, Petraglia F, Facchinetti F, et al. 1987. Effects of Org OD 14 on pituitary and peripheral beta-endorphin in castrated rats and post-menopausal women. Maturitas, (Suppl 1):35-48.
27. Genazzani AR, Petraglia F, Facchinetti F, et al. 1988. Steroid replacement increase beta-endorphin and beta-lipotropin plasma levels in postmenopausal women. Gynecol Obstet Invest, 26:153-9.
28. Genazzani AR, Petraglia F, Mercuri N, et al. 1990. Effect of steroid hormones and antihormones on hypothalamic beta-endorphin concentrations in intact and castrated female rats. J Endocrinol Invest, 13:91-6.
29. Genazzani AR, Petraglia F, Purdy R H. 1996. The brain: source and target for sex steroid hormones. London: The Parthenon Publishing Group.
30. Gompel A, Kandouz M, Siromachkova M, et al. 1997. The effects of tibolone on proliferation, differentiation and apoptosis in human breast cells. Gynecol Endocrinol, 11 (Suppl 1):77-9.
31. Hammar M, Christau S, Nathorst-Boos J, et al. 1998. A double blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol, 105:904-11.
32. Kenemans P, Speroff L for the International Tibolone Consensus Group. 2005. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group 2005. Maturitas, 16:51:21-8.
33. Kloosterboer HJ. 2004. Tissue-selectivity: the mechanism of action of tibolone. Maturitas, 48(Suppl 1):S30-40.
34. Kuh D, Wadsworth M, Hardy R. 1997. Women's health in midlife: the influence of the menopause, social factors and health in earlier life. Br J Obstet Gynaecol, 104:923-33.
35. Laan E, van Lunsen RH. 2001. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric, 4:28-41.
36. Lauritzen C, Studd J. 2005. Current management of menopause. London: Taylor and Francis.
37. Linghtman SL, Jacobs HS, Maguire AK. 1981. Climateric flushing: clinical and endocrine response to infusion of naloxone. Br J Obstet Gynaecol, 88:919-24.
38. Majewska MD. 1992. Neurosteroids: endogenous bimodal modulators of the GABA A receptors. Mechanism of action and physiological significance. Prog Neurobiol, 38:379-95.
39. McEwen BS, Alves SH. 1999. Estrogen actions in the central nervous system. Endocr Rev, 20:279-307.
40. McEwen BS. 1999. Clinical review 108: The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab, 84:1790-7.
41. Meeuwsen IB, Samson MM, Duursma SA, et al. 2002. The influence of tibolone on quality of life in postmenopausal women. Maturitas, 41:35-43.
42. Modelska K, Cummings S. 2002. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab, 87:16-23.
43. Nathorst-Böös J, Hammar M. 1997. Effect on sexual life-a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas, 26:15-20.
44. Pan HA, Wang ST, Pai MC, et al. 2003. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. J Reprod Med, 48:375-80.
45. Petraglia F, Comitini G, Genazzani AR. 1993. -Endorphin in human reproduction. In Herz A (ed). Opioids II. Berlin: Springer-Verlag. p 763-80.
46. Pluchino N, Genazzani AD, Bernardi F, et al. 2005. Tibolone, transdermal estradiol or oral estro-progestin therapies: effects on circulating allopregnanolone, cortisol and DHEA levels. Gynecol Endocrinol, 20:144-9.
47. Reed MJ, Kloosterboer HJ. 2004. Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas, 48(Suppl 1):S4-6.
48. Register TC, Wagner JD, Zhang L, et al. 2002. Effects of tibolone and conventional hormone replacement therapies on arterial and hepatic cholesterol accumulation and on circulating endothelin-1, vascular cell adhesion molecule-1, and E-selectin in surgically menopausal monkeys. Menopause, 9:411-21
49. Rosen R, et al (eds). 2002. Androgen Insufficiency in women: the Princeton Conference. Fertil Steril, 77(Suppl 4):S1-99.
50. Ross R, Paganni Hill A, Wan P, et al. 2000. Effect of hormone replacement therapy on breast cancer risk; estrogen versus estrogen plus progestin. J Natl Cancer Inst, 92:328-32.
51. Schoonen WG, Deckers GH, de Gooijer ME, et al. 2000. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol, 74:213-22.
52. Sherwin BB. 1991. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab, 72:336-43.
53. Sherwin BB. 1997. Estrogen effects on cognition in menopausal women. Neurology, 48:S21-6.
54. Short M. 2003. Menopause, mood and management. Climacteric, 6(Suppl 2):33-6.
55. Stahl SM. 2001. Sex and psychopharmacology. Is natural estrogen a psychotropic drug in women? Arch Gen Psychiatry, 58:537.
56. Stomati M, Bernardi F, Luisi S, et al. 2002. Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and beta-endorphin. Maturitas, 43:195-206.
57. Stomati M, Bersi C, Rubino S, et al. 1997. Neuroendocrine effects of different estradiol-progestin regimens in postmenopausal women. Maturitas, 28:127-35.
58. ∼-5 ‡ 4-isomerase activity associated with the human 17β-hydroxysteroid dehydrogenase type II isoform. J Clin Endocrino Metab, 85:3669-72.
59. Tang B, Markiewicz L, Kloosterboer HJ, et al. 1993. Human endometrial. 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol, 45:345-51.
60. Tax L, Goorissen E, Kicovic P. 1987. Clinical profile of Org OD 14. Maturitas, (Suppl 1):3-13.
61. Timmer C, Houwing NS. 2002. Dose proportionality of three different doses of tibolone. Pharmacotherapy, 22:6-13.
62. Valdivia I, Ortega D. 2000. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest, 20:101-7.
63. Zdravkovic M, Mueller M, Larsen S, et al. 2001. Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. Int J Clin Pharmacol Ther, 39:41-6.